SomaLogic

👇 Read our latest case study and explore how unbiased proteomics can drive novel diagnostic and therapeutic developments! https://somalogic.com/eyeing-thousands-of-proteins-for-biomarker-discovery/?utm_source=LI&utm_medium=SM

By leveraging the unmatched precision of the SomaScan™ high-plex proteomic platform, researchers are uncovering new strategies for diagnosing and treating diseases that affect the eyes as well as the entire body. From retinitis pigmentosa to Parkinson’s disease, understanding disease mechanisms has never been more promising.

Lower coefficients of variation mean greater confidence in a platform’s reproducibility - and greater confidence in your data.

Download our poster on optimizing biomarker discovery with a focus on low coefficient of variation in large-scale proteomics:

Optimizing biomarker discovery with focus on low coefficient of variation Median CVs range from ~4.5% to 18.0% for immunoassay technology, up to >30% for mass spectrometry, ~5% for the SomaScan® Assay, and ~10% for the Olink Explore Assay. Large CVs can cause technical variability to overwhelm biological signal.